Concord Biotech completes ANVISA inspection at Limbasi API facility

The positive outcome of Brazil's ANVISA inspection at the Limbasi facility clears a key regulatory hurdle, allowing entry into a massive geographic market for its fermentation-based APIs. This expands the company's export revenue potential and eliminates regulatory risk for this specific asset. The positive structural development supports a bullish swing or positional trajectory over the multi-week timeframe.

Price at alert: ₹1346.6